Antibody

1,010개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,010 programs
AntibodyLimited DatastaleTianjin Medical University Canc…Preclinical

Enituzumab injection+Abesili tablets+Anastrozole tablets (Enituzumab injection+Abesili tablets+Anastrozole tablets)

Advanced HR+ HER2 Negative Breast Carcinoma · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#AdvancedHR+HER2NegativeBreastCar+1
Trials 1Status Active
AntibodyLimited DatastaleFox Chase Cancer CenterPhase 2

pembrolizumab (Keytruda, Epacadostat + pembrolizumab)

Recurrent/ Metastatic Endometrial Carcinoma · Recurrent/ Metastatic Endometrial Carcin

#RecurrentMetastaticEndometrialCa#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Discontinued
AntibodyLimited DatastaleUniversity of Maryland, Baltimo…Phase 2

Erenumab-Aooe (Erenumab-Aooe)

Trigeminal Neuropathy · Trigeminal Neuropathy

#TrigeminalNeuropathy#Antibody#Phase2#monoclonal-antibody#University
Trials 1Status Discontinued
AntibodyLimited DatastaleEli Lilly and CompanyPhase 2

Etesevimab (Etesevimab)

COVID-19 · COVID-19

#COVID-19#Antibody#Phase2#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Etigilimab (Etigilimab)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#monoclonal-antibody#MD
Trials 1Status Recruiting
AntibodyLimited DatastaleFundación de Investigación Biom…Preclinical

ustekinumab (Stelara, Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab)

Inflammatory Bowel Disease · Inflammatory Bowel Disease

#InflammatoryBowelDisease#Antibody#Preclinical#monoclonal-antibody#Fundacin
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix)

Primary Central Nervous System Lymphoma · Primary Central Nervous System Lymphoma

#PrimaryCentralNervousSystemLymph#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 3

Experimental: mXELOX plus cetuximab (Experimental: mXELOX plus cetuximab)

Colo-rectal Cancer · Colo-rectal Cancer

#Colo-rectalCancer#Antibody#Phase3#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleBiogenPhase 2

FCR + Lumiliximab (FCR + Lumiliximab)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#monoclonal-antibody#Biogen
Trials 1Status Discontinued
AntibodyLimited DatastaleAbbViePhase 2

adalimumab (Humira, FITC-Adalimumab)

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Phase2#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleInstitut für Klinische Krebsfor…Phase 3

trastuzumab (Herceptin, FLOT + Herceptin/Pertuzumab)

Stomach Cancer; Gastroesophageal Junction Cancer · Stomach Cancer

#StomachCancer#Antibody#Phase3#monoclonal-antibody#GastroesophagealJunctionCancer+1
Trials 1Status Active
AntibodyLimited DatastaleMedical University of ViennaPhase 2

atezolizumab (Tecentriq, FMT combined with Atezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Medical
Trials 1Status Active
AntibodyLimited DatastaleNanogen Pharmaceutical Biotechn…Phase 3

Faceptor (Faceptor)

Breast Cancer Metastatic; Breast Cancer Recurrent · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase3#monoclonal-antibody#BreastCancerRecurrent+1
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

Faminitib or bevacizumab (Faminitib or bevacizumab)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#monoclonal-antibody#Fudan
Trials 1Status Recruiting
AntibodyLimited DatastaleHI-Bio, A Biogen CompanyPhase 2

Felzartamab (Felzartamab)

Immunoglobulin A (IgA) Nephropathy · Immunoglobulin A (IgA) Nephropathy

#ImmunoglobulinAIgANephropathy#Antibody#Phase2#monoclonal-antibody#HI-Bio
Trials 1Status Active
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 1Status Discontinued

26 / 51 pages

← PreviousNext →